Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

28.95 +0.38 (+1.33%)
Streaming Delayed Price Updated: 12:32 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Amphastar Receives FDA Approval for Vasopressin
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
News headline image
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating ↗
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
News headline image
Prometheus Biosciences Stock Shows Rising Relative Strength ↗
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
News headline image
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8% ↗
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
News headline image
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 ↗
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96 ↗
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before. 
Via Investor's Business Daily
News headline image
Kura Oncology Stock Scores Rising Relative Strength ↗
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier. 
Via Investor's Business Daily
News headline image
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 ↗
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92. 
Via Investor's Business Daily
News headline image
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
News headline image
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
69 Biggest Movers From Yesterday ↗
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday. 
Via Benzinga
News headline image
36 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) jumped 65% to $0.6382. 
Via Benzinga
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
News headline image
Amphastar Pharmaceuticals's Return On Capital Employed Insights ↗
Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) posted Q1 earnings of $24.25 million, an increase from Q4 of 22.74%. Sales dropped to $120.37 million, a 0.43% decrease between... 
Via Benzinga
News headline image
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot' ↗
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier. 
Via Investor's Business Daily
News headline image
Amphastar Receives FDA Approval for Regadenoson
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
News headline image
7 Safe Small-Cap Stocks to Buy Now ↗
If you're looking for resilient plays with high upside potential, consider these seven safe small-cap stocks to buy. 
Via InvestorPlace
News headline image
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022
Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
News headline image
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
News headline image
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
10 Stocks That Have Moved Over 20% Since The Indices Plummeted ↗
The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.  
Via Benzinga
News headline image
Why Top-Rated IBD 50 Stock Amphastar Pharmaceuticals Added To Its 75% Run ↗
FDA action just sent this red-hot biotech stock to a high, continuing its strong run. 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.